Quarterly report · Q3
9273.TEDINET S100TEGN
Period2023-07-01 → 2024-03-31
Filed2024-05-13
StandardJapan GAAP
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 33
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥16.8bn | 2023-07-01 → 2024-03-31 | Cons. | Net sales |
| Revenue | ¥22.1bn | 2022-07-01 → 2023-06-30 | Cons. | Net sales (5-year summary) |
| Revenue | ¥16.2bn | 2022-07-01 → 2023-03-31 | Cons. | Net sales |
| Operating income | ¥3.6bn | 2023-07-01 → 2024-03-31 | Cons. | Operating income |
| Operating income | ¥3.3bn | 2022-07-01 → 2023-03-31 | Cons. | Operating income |
| Ordinary income | ¥3.6bn | 2023-07-01 → 2024-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥4.1bn | 2022-07-01 → 2023-06-30 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥3.2bn | 2022-07-01 → 2023-03-31 | Cons. | Ordinary income |
| Profit before tax | ¥3.6bn | 2023-07-01 → 2024-03-31 | Cons. | Income before income taxes |
| Profit before tax | ¥3.2bn | 2022-07-01 → 2023-03-31 | Cons. | Income before income taxes |
| Net income (owners) | ¥2.3bn | 2023-07-01 → 2024-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥2.7bn | 2022-07-01 → 2023-06-30 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥2.1bn | 2022-07-01 → 2023-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥2.3bn | 2023-07-01 → 2024-03-31 | Cons. | Profit loss |
| Net income | ¥2.1bn | 2022-07-01 → 2023-03-31 | Cons. | Profit loss |
| Total assets | ¥30.0bn | at 2024-03-31 | Cons. | Assets |
| Total assets | ¥28.5bn | at 2023-06-30 | Cons. | Assets |
| Total assets | ¥27.5bn | at 2023-03-31 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥7.3bn | at 2024-03-31 | Cons. | Liabilities |
| Total liabilities | ¥7.5bn | at 2023-06-30 | Cons. | Liabilities |
| Net assets / equity | ¥22.7bn | at 2024-03-31 | Cons. | Net assets |
| Net assets / equity | ¥20.9bn | at 2023-06-30 | Cons. | Net assets |
| Net assets / equity | ¥20.3bn | at 2023-03-31 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥10.7bn | at 2024-03-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥10.8bn | at 2023-06-30 | Cons. | Cash and deposits |
| EPS (basic) | ¥57.1 | 2023-07-01 → 2024-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥17.64 | 2024-01-01 → 2024-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥67.83 | 2022-07-01 → 2023-06-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥52.48 | 2022-07-01 → 2023-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥17.29 | 2023-01-01 → 2023-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 75.7% | at 2024-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 73.5% | at 2023-06-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 73.7% | at 2023-03-31 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 28
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2023-07-01 → 2024-03-31 | −¥1.3bn |
| Reconciling Itemsreconciling | revenue intersegment | 2023-07-01 → 2024-03-31 | −¥1.3bn |
| Reconciling Itemsreconciling | segment profit | 2023-07-01 → 2024-03-31 | −¥11m |
| jpcrp040300-q3r_E34071-000Drug Substance Sales Businessreportable segment | revenue | 2023-07-01 → 2024-03-31 | ¥11.5bn |
| jpcrp040300-q3r_E34071-000Drug Substance Sales Businessreportable segment | revenue external | 2023-07-01 → 2024-03-31 | ¥10.3bn |
| jpcrp040300-q3r_E34071-000Drug Substance Sales Businessreportable segment | revenue intersegment | 2023-07-01 → 2024-03-31 | ¥1.3bn |
| jpcrp040300-q3r_E34071-000Drug Substance Sales Businessreportable segment | segment profit | 2023-07-01 → 2024-03-31 | ¥2.1bn |
| jpcrp040300-q3r_E34071-000Pharmaceutical Marketing Businessreportable segment | revenue | 2023-07-01 → 2024-03-31 | ¥6.5bn |
| jpcrp040300-q3r_E34071-000Pharmaceutical Marketing Businessreportable segment | revenue external | 2023-07-01 → 2024-03-31 | ¥6.5bn |
| jpcrp040300-q3r_E34071-000Pharmaceutical Marketing Businessreportable segment | segment profit | 2023-07-01 → 2024-03-31 | ¥1.5bn |
| —segment total | revenue | 2023-07-01 → 2024-03-31 | ¥18.0bn |
| —segment total | revenue external | 2023-07-01 → 2024-03-31 | ¥16.8bn |
| —segment total | revenue intersegment | 2023-07-01 → 2024-03-31 | ¥1.3bn |
| —segment total | segment profit | 2023-07-01 → 2024-03-31 | ¥3.6bn |
| Reconciling Itemsreconciling | revenue | 2022-07-01 → 2023-03-31 | −¥1.4bn |
| Reconciling Itemsreconciling | revenue intersegment | 2022-07-01 → 2023-03-31 | −¥1.4bn |
| Reconciling Itemsreconciling | segment profit | 2022-07-01 → 2023-03-31 | ¥16m |
| jpcrp040300-q3r_E34071-000Drug Substance Sales Businessreportable segment | revenue | 2022-07-01 → 2023-03-31 | ¥11.5bn |
| jpcrp040300-q3r_E34071-000Drug Substance Sales Businessreportable segment | revenue external | 2022-07-01 → 2023-03-31 | ¥10.2bn |
| jpcrp040300-q3r_E34071-000Drug Substance Sales Businessreportable segment | revenue intersegment | 2022-07-01 → 2023-03-31 | ¥1.4bn |
| jpcrp040300-q3r_E34071-000Drug Substance Sales Businessreportable segment | segment profit | 2022-07-01 → 2023-03-31 | ¥2.0bn |
| jpcrp040300-q3r_E34071-000Pharmaceutical Marketing Businessreportable segment | revenue | 2022-07-01 → 2023-03-31 | ¥6.0bn |
| jpcrp040300-q3r_E34071-000Pharmaceutical Marketing Businessreportable segment | revenue external | 2022-07-01 → 2023-03-31 | ¥6.0bn |
| jpcrp040300-q3r_E34071-000Pharmaceutical Marketing Businessreportable segment | segment profit | 2022-07-01 → 2023-03-31 | ¥1.2bn |
| —segment total | revenue | 2022-07-01 → 2023-03-31 | ¥17.5bn |
| —segment total | revenue external | 2022-07-01 → 2023-03-31 | ¥16.2bn |
| —segment total | revenue intersegment | 2022-07-01 → 2023-03-31 | ¥1.4bn |
| —segment total | segment profit | 2022-07-01 → 2023-03-31 | ¥3.3bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 356
| Item | Context | Value | Unit |
|---|---|---|---|
| Previous fiscal year end date | FilingDateInstant | 2023-06-30 | |
| Next fiscal year start date | FilingDateInstant | － | |
| End date of quarterly or semi annual period of next fiscal year | FilingDateInstant | － | |
| Amendment flag | FilingDateInstant | false | |
| Identification of document subject to amendment | FilingDateInstant | － | |
| Report amendment flag | FilingDateInstant | false | |
| Xbrl amendment flag | FilingDateInstant | false | |
| Business results of group (text) | FilingDateInstant | Text · Plus | |
| Description of business (text) | FilingDateInstant | Text · Plus | |
| Business risks (text) | FilingDateInstant | Text · Plus | |
| Management analysis of financial position operating results and cash flows (text) | FilingDateInstant | Text · Plus | |
| Critical contracts for operation (text) | FilingDateInstant | Text · Plus | |
| Total number of shares (text) | FilingDateInstant | Text · Plus | |
| Issued shares total number of shares etc (text) | FilingDateInstant | Text · Plus | |
| Class issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | Original text (Japanese)普通株式 | |
| Name of financial instruments exchange on which securities are listed or authorized financial instruments business association to which securities are registered | FilingDateInstant_OrdinaryShareMember | Original text (Japanese)東京証券取引所プライム市場 | |
| Description issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | Original text (Japanese)完全議決権株式であり、権利内容に何ら限定のない当社における標準となる株式であります。なお、単元株式数100株であります。 | |
| Details of employee share option program (text) | FilingDateInstant | Text · Plus | |
| Other information on share acquisition rights (text) | FilingDateInstant | Text · Plus | |
| Exercises etc of moving strike convertible bonds etc (text) | FilingDateInstant | Text · Plus | |
| Changes in number of issued shares stated capital etc (text) | FilingDateInstant | Text · Plus | |
| Major shareholders (text) | FilingDateInstant | Text · Plus | |
| Voting rights (text) | FilingDateInstant | Text · Plus | |
| Issued shares voting rights (text) | FilingDateInstant | Text · Plus | |
| Description issued shares voting rights | CurrentQuarterInstant_SharesWithNoVotingRightsMember | － | |
| Description issued shares voting rights | CurrentQuarterInstant_SharesWithRestrictedVotingRightsTreasurySharesEtcMember | － | |
| Description issued shares voting rights | CurrentQuarterInstant_SharesWithRestrictedVotingRightsOtherMember | － | |
| Description issued shares voting rights | CurrentQuarterInstant_SharesWithFullVotingRightsTreasurySharesEtcMember | － | |
| Description issued shares voting rights | CurrentQuarterInstant_SharesWithFullVotingRightsOtherMember | － | |
| Description issued shares voting rights | CurrentQuarterInstant_SharesLessThanOneUnitMember | － | |
| Treasury shares etc (text) | FilingDateInstant | Text · Plus | |
| Name of shareholder treasury shares etc | CurrentQuarterInstant_Row1Member | Original text (Japanese)コーア商事ホールディングス株式会社 | |
| Address of shareholder treasury shares etc | CurrentQuarterInstant_Row1Member | Original text (Japanese)神奈川県横浜市港北区日吉七丁目13番15号 | |
| Information about officers (text) | FilingDateInstant | Text · Plus | |
| Regulations in accordance with which consolidated financial statements have been prepared financial information | CurrentYTDDuration | Text · Plus | |
| Note on independent audit financial information | CurrentYTDDuration | Text · Plus | |
| Quarterly consolidated balance sheet (text) | CurrentYTDDuration | Text · Plus | |
| Year to quarter end consolidated statement of income (text) | CurrentYTDDuration | Text · Plus | |
| Year to quarter end consolidated statement of comprehensive income (text) | CurrentYTDDuration | Text · Plus | |
| Notes changes in scope of consolidation or equity method (text) | CurrentYTDDuration | Text · Plus | |
| Notes changes in accounting policies na quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Debtors notes regarding overdraft contracts and or loan commitments (text) | CurrentQuarterInstant | Text · Plus | |
| Notes regarding promissory notes due on balance sheet date (text) | CurrentQuarterInstant | Text · Plus | |
| Description of fact that quarterly statement of cash flows has not been prepared (text) | CurrentYTDDuration | Text · Plus | |
| Notes regarding dividend (text) | Prior1YTDDuration | Text · Plus | |
| Notes regarding dividend (text) | CurrentYTDDuration | Text · Plus | |
| Notes segment information etc quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Footnotes regarding segment information table (text) | Prior1YTDDuration | Text · Plus | |
| Information about impairment loss of non current assets or goodwill etc for each reportable segment (text) | Prior1YTDDuration | Text · Plus | |
| Footnotes regarding segment information table (text) | CurrentYTDDuration | Text · Plus |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 12 of 12 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |